[Comment] HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer

The benefits of targeted therapy for HER2-positive breast cancer are indisputable. Not only has the addition of trastuzumab to chemotherapy been consistently shown to improve survival,1–3 but also there are now three new, HER2-selective drugs available in the curative setting: pertuzumab, neratinib and trastuzumab emtansine. However, to properly calculate how aggressively to systemically treat an individual is complicated, which can be further exacerbated by an oncologist’s fear of unwittingly undertreating a patient and contributing to the development of incurable disease.

Lascia un commento